Navigation Links
BioCryst Reports Results From the First-Ever Completed Active-Controlled Phase 2 Study in Hospitalized Influenza
Date:10/27/2008

e adequate dosing by intramuscular injection may not be correct, that HHS and the Food & Drug Administration (FDA) may not agree with our analysis, that HHS may further condition, reduce or eliminate future funding of the peramivir program, that ongoing peramivir clinical trials may not be successful, that the peramivir program may not be successful, that the pivotal trial with forodesine HCl in cutaneous T-cell lymphoma (CTCL) may not meet its endpoint, that development and commercialization of forodesine HCl in CTCL may not be successful, that we or our licensees may not be able to enroll the required number of subjects in planned clinical trials of our product candidates and that such clinical trials may not be successfully completed, that BioCryst or its licensees may not commence as expected additional human clinical trials with our product candidates, that our product candidates may not receive required regulatory clearances from the FDA, that ongoing and future preclinical and clinical development may not have positive results, that we or our licensees may not be able to continue future development of our current and future development programs, that our development programs may never result in future product, license or royalty payments being received by BioCryst, that BioCryst may not be able to retain its current pharmaceutical and biotechnology partners for further development of its product candidates or it may not reach favorable agreements with potential pharmaceutical and biotechnology partners for further development of its product candidates, that our projected burn rate may not be consistent with our expectations, that BioCryst may not have sufficient cash to continue funding the development, manufacturing, marketing or distribution of its products and that additional funding, if necessary, may not be available at all or on terms acceptable to BioCryst. Please refer to the documents BioCryst files periodically with the Securities and Exchange Commi
'/>"/>
SOURCE BioCryst Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. BioCryst to Present at the BioCentury NewsMakers in the Biotech Industry Conference
2. BioCryst Reports Preliminary Results From a Phase II Clinical Trial of Peramivir in Subjects With Acute Influenza
3. BioCryst to Present at UBS 2007 Global Life Sciences Conference
4. BioCryst Strengthens Its Expertise in Clinical Development By Adding Thomas J. Simon, M.D. as Interim Chief Medical Officer To Meet Growing Product Development and Commercial Opportunities
5. BioCryst Pharmaceuticals to Announce Fourth Quarter and Fiscal Year 2007 Financial Results on March 4, 2008
6. BioCryst Reports Fourth Quarter and Year End 2007 Financial Results and Corporate Update
7. BioCryst Reports First Quarter 2008 Financial Results and Clinical Update
8. William P. Sheridan Appointed Chief Medical Officer of BioCryst Pharmaceuticals
9. BioCryst Pharmaceuticals To Announce Second Quarter 2008 Financial Results on August 7, 2008
10. BioCryst to Present at UBS 2008 Global Life Sciences Conference
11. BioCryst to Present at the JMP Healthcare Focus Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2015)... July 1, 2015 InferMed ... will ... evidence-based clinical s olutions suite   ... medical information products and services, announced today the acquisition of  ... support (CDS) technology company. InferMed,s Arezzo technology supports ...
(Date:6/30/2015)... Japan , July 1, 2015 R-Japan Co.,Ltd. ... on the Safety of Regenerative Medicine from the Ministry of ... on June 29, 2015. The fact that ... processing facility through the auditing from Pharmaceuticals and Medical Devices ... the application, allows it to provide stem cell manufacturing service ...
(Date:6/30/2015)... , June 30, 2015  NASA astronaut Kjell ... next month on his first mission to the International ... from 8 to 9 a.m. EDT Tuesday, July 7. ... in Star City, Russia . The interviews ... NASA Television highlighting his mission training. To schedule ...
(Date:6/30/2015)... ... June 30, 2015 , ... With its latest polyacrylonitrile (PAN) ... achieve faster flow rates in comparison to nylon or polyethersulfone (PES). Its ... allow easy liquid flow while trapping particulates as small as 0.2 micron in ...
Breaking Biology Technology:Elsevier Acquires InferMed, Provider of Clinical Decision Support Technology 2Elsevier Acquires InferMed, Provider of Clinical Decision Support Technology 3Elsevier Acquires InferMed, Provider of Clinical Decision Support Technology 4R-Japan Obtained Autologous Stem Cell Manufacturing License from the Ministry of Health, Labour and Welfare 2NASA Astronaut Preps for First Space Station Mission, Available for Media Interviews 2New Nanofiber Membrane Provides Fast, Efficient Filtration 2
... KONG, April 22 /Xinhua-PRNewswire/ -- Fufeng Group Limited,("Fufeng" ... as "the Group"; HKEx: 546), a leading vertically ... its,annual results for the year ended 31 December ... increased sales volume of major,products, the Group,s turnover ...
... by the Project on Emerging Nanotechnologies (PEN) indicates ... much as the U.S. in research primarily aimed ... analysis also highlights a substantial over-inflation of the ... U.S. , The new PEN assessment of ...
... Revenues, $0.03 Net Loss Per Share, SAN JOSE, ... VNUS ), a leading provider of medical devices,for the ... results for the first quarter ended March 31, 2008., ... increased 21% to $18.9,million compared with $15.6 million for ...
Cached Biology Technology:Fufeng Announces 2007 Annual Results 2Fufeng Announces 2007 Annual Results 3Europe spends nearly twice as much as US on nanotech risk research 2VNUS Medical Technologies Reports First-Quarter 2008 Results: 21% growth in Net Revenues and 51% Growth in Unit Sales 2VNUS Medical Technologies Reports First-Quarter 2008 Results: 21% growth in Net Revenues and 51% Growth in Unit Sales 3VNUS Medical Technologies Reports First-Quarter 2008 Results: 21% growth in Net Revenues and 51% Growth in Unit Sales 4VNUS Medical Technologies Reports First-Quarter 2008 Results: 21% growth in Net Revenues and 51% Growth in Unit Sales 5VNUS Medical Technologies Reports First-Quarter 2008 Results: 21% growth in Net Revenues and 51% Growth in Unit Sales 6VNUS Medical Technologies Reports First-Quarter 2008 Results: 21% growth in Net Revenues and 51% Growth in Unit Sales 7
(Date:6/16/2015)... QUEBEC CITY , June 16, 2015 /CNW ... announce their partnership centralized around the incorporation of ... mobile point-of-care diagnostic laboratory, the Mo-POD™. This unprecedented ... the BIO International Conference at the ... from June 15 th to ...
(Date:6/16/2015)... Fingerprint Cards has received an order of 375 ... from one of its module partners in Asia ... the third quarter 2015. The sensors will be used by ... Jörgen Lantto, CEO of FPC, comments: " This order   ... smartphone OEMs in integrating touch fingerprint sensors in   their ...
(Date:6/15/2015)... 16, 2015 According to a ... Type (Rule-Based, Statistical, and Hybrid), Technologies (Recognition, IVR, OCR, ... published by MarketsandMarkets, The Natural Language Processing Market is ... of 18.4% for the forecast period 2015-2020. ... F igures spread   through 155 P ...
Breaking Biology News(10 mins):handyem and FlowMetric Diagnostics announce their partnership in the development of Flow Cytometry- Based Solutions in diagnostic capabilities 2handyem and FlowMetric Diagnostics announce their partnership in the development of Flow Cytometry- Based Solutions in diagnostic capabilities 3FPC Receives Order for Touch Fingerprint Sensors of 375 MSEK 2Natural Language Processing Market Worth $13.4 Billion by 2020 2Natural Language Processing Market Worth $13.4 Billion by 2020 3Natural Language Processing Market Worth $13.4 Billion by 2020 4Natural Language Processing Market Worth $13.4 Billion by 2020 5
... Bethesda, MD FASEB MARC (Maximizing Access to ... recipients for the American Association of Immunologists 2013 ... from July 13-18, 2013. These awards are meant ... scientists from underrepresented groups into the mainstream of ...
... progress in the search for the first broad-spectrum drugs ... common infectious diseases. Their study on these potential drugs ... the journal ACS Medicinal Chemistry Letters . ... HRV infections cause mild disease, they can lead to ...
... teachers to sing melodies accurately, according to a new ... the University of Kaiserslautern in Germany. Their analysis of ... songbirds, brain processes. The work is published online in ... is considered to be one of the most complex ...
Cached Biology News:Songbirds turn on and tune up 2